Ключові слова
інсулінорезистентність
метформін
Як цитувати
Анотація
Представлені епідеміологічні докази зв’язку інсулінорезистентності з ризиком розвитку раку ендометрія. Розглянуті канцерогенні ефекти пов’язаних з інсулінорезистентністю чинників і узагальнені результати досліджень застосування метформінe – препарату, що підвищує чутливість тканин до інсуліну, у хворих з гіперпластичними процесами ендометрія і раком ендометрія.Посилання
World Health Organization. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. – Режим доступа: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
Key T.J. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk / T.J. Key, M.C. Pike // Br. J. Cancer. – 1988. – Vol. 57, № 2. – Р. 205–212.
Рrospective evaluation of glucose tolerance and insulin resistance among patients with endometrial cancer and atypical endometrial hyperplasia / A. Mitsuhashi, S. Hanawa, N. Yamamoto et al.: 39th ESMO Congress, 26–30 september 2014, Madrid, Spain // Ann. Oncol. (Suppl.4). – 2014. – 928 р.
Prospective evaluation of insulin resistance among endometrial cancer patients / J.K. Burzawa, K.M. Schmeler, P.T. Soliman et al. // Am. J. Obstet. Gynecol. – 2011. – Vol. 204, № 4. – Р. 355.e1–355.e7.
Case-control study of markers of insulin resistance and endometrial cancer risk / C.M. Friedenreich, A.R. Langley, T.P. Speidel et al. // Endocr. Relat. Cancer. – 2012. – Vol. 19, № 6. – Р. 785–792.
Berstein L.M. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer / L.M. Berstein, J.O. Kvatchevskaya, T.E. Poroshina // J. Cancer Res. Clin. Oncol. – 2004. – Vol. 130, № 11. – Р. 687–693.
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer / M.J. Gunter, D.R. Hoover, H. Yu et al. // Cancer Epidemiol. Biomarkers Prev. – 2008. – Vol. 17, № 4 – Р. 921–929.
Hyperinsulinemia is associated with endometrial hyperplasia and disordered proliferative endometrium: a prospective cross-sectional study / W. Shan, C. Ning, X. Luo et al. // Gynecol. Oncol. – 2014. – Vol. 132, № 3. – Р. 606–610.
Jenabi E. The effect of body mass index on endometrial cancer: a meta-analysis / E. Jenabi, J. Poorolajal // Public Health. – 2015. – Vol. 129, № 7. – Р. 872–880.
Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies / C. Liao, D. Zhang, C. Mungo et al. // Gynecol. Oncol. – 2014. – Vol. 35, № 1. – Р. 163–171.
Barry J.A. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis / J.A. Barry, M.M. Azizia, P.J. Hardiman // Hum. Reprod. Update. – 2014. – Vol. 20, № 5. – Р. 748–758.
Preliminary investigation of the expression and functions of insulin receptor isoforms in endometrial carcinoma / G. Zhang, X.P. Li, J.L. Wang, L.H. Wei // Zhonghua Fu Chan Ke Za Zhi. – 2012. – Vol. 47, № 11. – P. 839–845.
Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth / C.F. Wang , G. Zhang, L.J. Zhao et al. // PLoS One. – 2013. – Vol. 8, № 8. – Р. e69001.
Ogawa K. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade / K. Ogawa, C. Sun, A. Horii // Oncol. Rep. – 2005. – Vol. 14, № 6. – Р. 1481–1485.
Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent / Y. Wang, S. Hua, W. Tian et al. // Gynecol Oncol. – 2012. – Vol. 125, № 3. – Р. 734–741.
Extracellular signal-regulated protein kinase activation in endometrium with polycystic ovary syndrome and its significance / X.R. Song, H.Y. Zhang, Y.F. Zhang et al. // Zhonghua Fu Chan Ke Za Zhi. – 2010. – Vol. 45, № 10. – Р. 767–771.
Nahum R. Metabolic regulation of androgen production by human thecal cells in vitro / R. Nahum, K.J. Thong , S.G. Hillier // Hum. Reprod. – 1995. – Vol. 10, № 1. – Р. 75–81.
Fottner C. Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins / C. Fottner, D. Engelhardt, M.M. Weber // J. Endocrinol. – 1998. – Vol. 158, № 3. – Р.409–417.
Insulin and hyperandrogenism in women with polycystic ovary syndrome / C.G. Baptiste, M.C. Battista, A. Trottier et al. // J. Steroid Biochem. Mol. Biol. – 2010. – Vol. 122, № 1–3. – Р. 42–52.
Kalme Т. Comparative studies on the regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells / T. Kalme, H. Koistinen, M. Loukovaara // J. Steroid Biochem. Mol. Biol. – 2003. – Vol. 86, № 2. – Р. 197–200.
Study on relationship between endogenous androgens and insulin resistance at the different stages of postmenopause / Y.K. Cao, S.F. Zhang, S.E. Zou et al. // Zhonghua Fu Chan Ke Za Zhi. – 2013. – Vol. 48, № 10. – Р. 740–744.
The effect of insulin on aromatase activity in isolated human endometrial glands and stroma / J.F. Randolph Jr., S. Kipersztok, J.W. Ayers et al. // Am. J. Obstet. Gynecol. – 1987. – Vol. 157, № 6. – Р. 1534–1539.
FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer / M. Qiu, W. Bao, J. Wang et al. // BMC Cancer. – 2014. – Vol. 14. – Р. 78.
Особенности гормонально-энергетического обмена у больных с гиперпластическими процессами и раком эндометрия на фоне метаболического синдрома / А.Л. Чернышова, Л.А. Коломиец, Н.В. Юнусова, Е.В. Шаншашвили // Сибирск. онкол. журнал. – 2015. – № 1. – С. 5–12.
Li L. Pathological and immunohistochemical study on estrogen and progesterone receptors in endometrium of polycystic ovarian syndrome / L. Li, C. Yang, J. Qiao // Zhonghua Fu Chan Ke Za Zhi. – 1998. – Vol. 33, № 2. – Р. 89–91.
Lee I.I. Influence of AKT on progesterone action in endometrial diseases / I.I. Lee, J.J. Kim // Biol. Reprod. – 2014. – Vol. 91, № 3. – Article 63.
Huijgens A.N. Factors predicting recurrent endometrial cancer / A.N. Huijgens, H.J. Mertens // Facts Views Vis. Obgyn. – 2013. – Vol. 5, № 3. – Р. 179–186.
Yanase T. Sex hormones and metabolic function / T. Yanase ,
M. Tanabe , T. Nomiyama // Nihon. Rinsho. – 2015. – Vol. 73, № 4. – Р. 571–575.
Suba Z. Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis / Z. Suba // Pathol. Oncol. Res. – 2012. –
Vol. 18, № 2. – Р. 123–133.
Tumor necrosis factor (TNF)-α, soluble TNF receptors and endometrial cancer risk: the EPIC study / L. Dossus, S. Becker, S. Rinaldi et al. // Int. J. Cancer. – 2011. – Vol. 129, № 8. – Р. 2032–2037.
Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study / L. Dossus, S. Rinaldi, S. Becker et al. // Endocr. Relat. Cancer. – 2010. – Vol. 17, № 4. – Р. 1007–1019.
The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma / H.O .Smith, N.D. Stephens, C.R. Qualls et al. // Mol. Oncol. – 2013. – Vol. 7, № 1. – Р. 41–54.
Obesity and the endometrium: adipocyte-secreted proinflammatory TNF-α cytokine enhances the proliferation of human endometrial glandular cells / S. Nair, H. Nguyen, S. Salama, A. Al-Hendy // Obstet. Gynecol. Int. – 2013. – Vol. 2013. – Аrticle 368543.
Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-κB signaling pathway / Q. Che, B.Y. Liu, F.Y Wang et al. // Biochem. Biophys. Res. Commun. – 2014. – Vol. 446, №1. – Р. 167–172.
Effect of tumor necrosis factor- on estrogen metabolism and endometrial cells: potential physiological and pathological relevance / S.A. Salama, M.W. Kamel, C.R. Diaz-Arrastia et al. // J. Clin. Endocrinol. Metab. – 2009. – Vol. 94, № 1. – Р. 285–293.
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17β-estradiol biosynthesis in endometrial carcinoma microenvironment / Q. Che, B.Y. Liu, Y. Liao et al. // Int. J. Cancer. – 2014. –Vol. 135, № 2. – Р. 282–294.
Novel insights in SHBG regulation and clinical implications / R. Simó, C. Sáez-López, A. Barbosa-Desongles et al. // Trends Endocrinol. Metab. – 2015. – Vol. 26, № 7. – Р. 376–383.
Endogenous peptides as risk markers to assess the development of insulin resistance / P. Fang, M. Shi, M. Yu et al. // Peptides. – 2014. – Vol. 51. – Р. 9–14.
Zheng Q. Circulating adiponectin and risk of endometrial cancer / Q. Zheng, H. Wu, J. Cao // PLoS One. – 2015. – Vol. 10, № 6. – Р. e0129824.
Expression of adiponectin receptors and its possible implication in the human endometrium / Y. Takemura, Y. Osuga, T. Yamauchi et al. // Endocrinology. – 2006. – Vol. 147, № 7. – Р. 3203–3210.
Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2 / L. Cong, J. Gasser, J. Zhao et al. // Endocr. Relat. Cancer. – 2007. – Vol. 14, № 3. – Р. 713–720.
Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway / L. Zhang, K. Wen, X. Han et al. // Gynecol. Oncol. – 2015. – Vol. 137, № 2. – Р. 311–320.
Association between serum leptin concentrations and insulin resistance: a population-based study from China / H. Zuo, Z. Shi, B. Yuan et al. // PLoS One. – 2013. – Vol. 8, № 1. – Р. e54615.
High leptin level is an independent risk factor of endometrial cancer: a meta-analysis / P.P. Wang, X.Y. He, R. Wang et al. // Cell Physiol. Biochem. – 2014. – Vol. 34, № 5 – Р. 1477–1484.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells / J. Gao, J. Tian, Y. Lv et al. // Cancer Sci. – 2009. – Vol. 100, № 3. – Р. 389–395.
Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer / Y. Zhang, L. Liu, C. Li, H. Ai // Cancer Biomark. – 2014. – Vol. 14, № 5. – Р. 353–359.
Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways / D. Sharma, N.K. Saxena, P.M. Vertino, F.A. Anania // Endocr. Relat. Cancer. – 2006. – Vol. 13, № 2. – Р. 629–640.
Leptin promotes human endometrial carcinoma cell proliferation by enhancing aromatase (P450arom) expression and estradiol formation / L. Liu, L. Wang, J. Zheng, G. Tang // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2013. – Vol. 170, № 1. – Р. 198–201.
Leptin inhibits the apoptosis of endometrial carcinoma cells through activation of the nuclear factor κB-inducing kinase/IκB kinase pathway / X. Zhou, H. Li, Y. Chai, Z. Liu // Int. J. Gynecol. Cancer. – 2015. – Vol. 25, № 5. – Р. 770–778.
Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells / C. Carino, A.B. Olawaiye, S. Cherfils et al. // Int. J. Cancer. – 2008. – Vol. 123, № 12. – Р. 2782–2790.
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1 / L.J. Ma, S.L. Mao, K.L. Taylor et al. // Diabetes. – 2004. – Vol. 53, № 2. – Р. 336–346.
Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan / Y.Y. Chou, W.H. Sheu, Y.J. Tang et al. // Arch. Gerontol. Geriatr. – 2009. – Vol. 49 (Suppl 2). – Р. S41–S45.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer / C. Tecimer, D.L. Doering, L.J. Goldsmith et al. // Gynecol. Oncol. – 2001. – Vol. 80, № 1. – Р. 48–55.
Фактор роста эндотелия сосудов и компоненты системы активации плазминогена при раке и гиперплазии эндометрия / E.C. Герштейн, Е.В. Грицаенко, М.Е. Щербаков и др. // Вопросы онкологии. – 2003. – Т. 49, № 6. – С. 725–729.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer / E. Steiner, K. Pollow, D. Hasenclever et al. // Gynecol. Oncol. – 2008. – Vol. 108, № 3. – Р. 569–567.
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study / S. Dariusz, M. Agnieszka, R. Elzbieta et al. // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2012. – Vol.163, № 2. – Р. 193–199.
Kasznicki J. Metformin in cancer prevention and therapy / J. Kasznicki, A. Sliwinska, J. Drzewoski // Ann. Transl. Med. – 2014. – Vol. 2, № 6. – Р. 57.
Cellular and molecular mechanisms of metformin: an overview / B. Viollet, B. Guigas, N.S. Garcia et al. // Clin. Sci. (Lond). – 2012. – Vol. 122, № 6. – Р. 253–270.
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway / R.K. Hanna, C. Zhou, K.M. Malloy et al. // Gynecol. Oncol. – 2012. – Vol. 125, № 2. – Р. 458–469.
Another surprise from Metformin: Novel mechanism of action via K-Ras influences endometrial cancer response to therapy / D.A. Iglesias, M.S. Yates, D. van der Hoeven et al. // Mol. Cancer Ther. – 2013. – Vol. 12, № 12. – Р. 2847–2856.
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy / L.A. Cantrell, C. Zhou, A. Mendivil et al. // Gynecol. Oncol. – 2010. – Vol. 116, № 1. – Р. 92–98.
AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer / H. Motoshima, B.J. Goldstein, M. Igata, E. Araki // J. Physiol. – 2006. – Vol. 574 (Pt 1). – Р. 63–71.
Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R / Y. Zhang, M.X. Li, H. Wang et al. // Asian Pac. J. Cancer Prev. – 2015. – Vol. 16, № 1. – Р. 221–225.
Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis / A. Takahashi, F. Kimura, A.Yamanaka et al. // Cancer Cell Int. – 2014. – Vol. 14. – Р. 53.
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase / K.A. Brown, N.I. Hunger, M. Docanto et al. // Breast Cancer Res. Treat. – 2010. – Vol. 123, № 2. – Р. 591–596.
Effects of metformin on the estrogen-induced proliferation and the expression of ER in human endometrial cancer cells / J. Zhang, B. Zhang, Z. Yin et al. // Zhonghua Fu Chan Ke Za Zhi. – 2014. – Vol. 49, № 12. – Р. 932–937.
Does metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer ? / A. Markowska, M. Pawałowska, V. Filas et al. // Diabetol. Metab. Syndr. – 2013. – Vol. 5, № 1. – Р. 76.
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells / Y. Xie, Y.L. Wang, L. Yu et al. // J. Steroid Biochem. Mol. Biol. – 2011. – Vol. 126, № 3–5. – Р. 1113–1120.
Paradoxic effects of metformin on endothelial cells and angiogenesis /
K. Dallaglio, A. Bruno, A.R. Cantelmo et al. // Carcinogenesis. – 2014. – Vol. 35, № 5. – Р. 1055–1066.
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells / B.K. Tan, R. Adya, J. Chen et al. // J. Clin. Endocrinol. Metab. –2011. – Vol. 96, № 3. – Р. 808–816.
Metformin reduces endogenous reactive oxygen species and associated DNA damage / C. Algire, O. Moiseeva, X. Deschênes-Simard et al. // Cancer Prev. Res (Phila). – 2012. – Vol. 5, № 4. – Р. 536–543.
Immune-mediated antitumor effect by type 2 diabetes drug, metformin / S. Eikawa, M. Nishida, S. Mizukami et al. // Proc. Natl. Acad. Sci. USA. – 2015. – Vol. 112, № 6. – Р. 1809–1814.
Metformin and the risk of endometrial cancer: a case-control analysis / C. Becker, S.S. Jick, C.R. Meier, M..Bodmer // Gynecol. Oncol. – 2013. – Vol. 129, № 3. – Р. 565–569.
Association between diabetes, diabetes treatment and risk of developing endometrial cancer / J. Luo, S. Beresford, C. Chen et al. // Br. J. Cancer. – 2014. – Vol. 111, № 7. – Р. 1432–1439.
Tseng C.H. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan / C.H. Tseng // Gynecol. Oncol. – 2015. – Vol. 138, № 1. –
Р. 147–153.
Metformin is associated with improved survival in endometrial cancer / E.M. Ko, P. Walter, A. Jackson et al. // Gynecol. Oncol. – 2014. – Vol. 132, № 2. – Р. 438–442.
Metformin use and endometrial cancer survival / N.S. Nevadunsky, A. Van Arsdale, H.D. Strickler et al. // Gynecol. Oncol. – 2014. – Vol. 132, № 1. – Р. 236–240.
Zhang Z.J. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis / Z.J. Zhang, S. Li // Diabetes Obes. Metab. – 2014. – Vol. 16, № 8. – Р. 707–710.
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer / I. Laskov, L. Drudi, M.C. Beauchamp et al. // Gynecol. Oncol. – 2014. – Vol. 134, № 3. – Р. 607–614.
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer / K.M. Schuler, B.S. Rambally, M.J. DiFurio et al. // Cancer Med. – 2015. – Vol. 4, № 2. – Р. 161–173.
Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial / A. Mitsuhashi, T. Kiyokawa, Y. Sato, M. Shozu // Cancer. – 2014. – Vol. 120, № 19. – Р. 2986–2995.
Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent / D.R. Session, K.R. Kalli, I.S. Tummon et al. // Gynecol. Endocrinol. – 2003. –– Vol. 17, № 5. – Р. 405–407.
Shen Z.Q. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives / Z,Q, Shen, H.T. Zhu, J.F. Lin // Obstet. Gynecol. – 2008. – Vol. 112, № 2 (Pt 2). – Р. 465–467.
Stanosz S. An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women / S. Stanosz // Eur. J. Gynaecol. Oncol. – 2009. – Vol. 30, № 4. – Р. 365–369.
Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance / X. Li, J.R. Guo, J.F. Lin et al. // J. Cancer. – 2014. – Vol. 5, № 3. – Р. 173–181.
A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer: ASCO Annual Meeting, 2014 / A. Mitsuhashi, H. Usui, Y. Satoh et al. // J. Clin. Oncol. – Vol. 32, № 15 (Suppl.). – Аbstr. 5592.
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer / H.J. Mackay, E.A. Eisenhauer, S. Kamel-Reid et al. // Cancer. – 2014. – Vol. 120, № 4. – Р. 603–610.
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression / L. Dong, Q. Zhou, Z. Zhang et al. // J. Obstet. Gynaecol. Res. – 2012. – Vol. 38, № 8. – Р. 1077–1085.